Price Graph
Price
Yield
These terms and conditions govern your use of the website alphaminr.com and its related services.
These Terms and Conditions (“Terms”) are a binding contract between you and Alphaminr, (“Alphaminr”, “we”, “us” and “service”). You must agree to and accept the Terms. These Terms include the provisions in this document as well as those in the Privacy Policy. These terms may be modified at any time.
Your subscription will be on a month to month basis and automatically renew every month. You may terminate your subscription at any time through your account.
We will provide you with advance notice of any change in fees.
You represent that you are of legal age to form a binding contract. You are responsible for any
activity associated with your account. The account can be logged in at only one computer at a
time.
The Services are intended for your own individual use. You shall only use the Services in a
manner that complies with all laws. You may not use any automated software, spider or system to
scrape data from Alphaminr.
Alphaminr is not a financial advisor and does not provide financial advice of any kind. The service is provided “As is”. The materials and information accessible through the Service are solely for informational purposes. While we strive to provide good information and data, we make no guarantee or warranty as to its accuracy.
TO THE EXTENT PERMITTED BY APPLICABLE LAW, UNDER NO CIRCUMSTANCES SHALL ALPHAMINR BE LIABLE TO YOU FOR DAMAGES OF ANY KIND, INCLUDING DAMAGES FOR INVESTMENT LOSSES, LOSS OF DATA, OR ACCURACY OF DATA, OR FOR ANY AMOUNT, IN THE AGGREGATE, IN EXCESS OF THE GREATER OF (1) FIFTY DOLLARS OR (2) THE AMOUNTS PAID BY YOU TO ALPHAMINR IN THE SIX MONTH PERIOD PRECEDING THIS APPLICABLE CLAIM. SOME STATES DO NOT ALLOW THE EXCLUSION OR LIMITATION OF INCIDENTAL OR CONSEQUENTIAL OR CERTAIN OTHER DAMAGES, SO THE ABOVE LIMITATION AND EXCLUSIONS MAY NOT APPLY TO YOU.
If any provision of these Terms is found to be invalid under any applicable law, such provision shall not affect the validity or enforceability of the remaining provisions herein.
This privacy policy describes how we (“Alphaminr”) collect, use, share and protect your personal information when we provide our service (“Service”). This Privacy Policy explains how information is collected about you either directly or indirectly. By using our service, you acknowledge the terms of this Privacy Notice. If you do not agree to the terms of this Privacy Policy, please do not use our Service. You should contact us if you have questions about it. We may modify this Privacy Policy periodically.
When you register for our Service, we collect information from you such as your name, email address and credit card information.
Like many other websites we use “cookies”, which are small text files that are stored on your computer or other device that record your preferences and actions, including how you use the website. You can set your browser or device to refuse all cookies or to alert you when a cookie is being sent. If you delete your cookies, if you opt-out from cookies, some Services may not function properly. We collect information when you use our Service. This includes which pages you visit.
We use Google Analytics and we use Stripe for payment processing. We will not share the information we collect with third parties for promotional purposes. We may share personal information with law enforcement as required or permitted by law.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x
|
QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
|
o
|
TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT
|
|
PLURISTEM THERAPEUTICS INC.
|
|
(Exact name of registrant as specified in its charter)
|
|
Nevada
|
98-0351734
|
|
(State or other jurisdiction of incorporation or organization)
|
(IRS Employer Identification No.)
|
|
MATAM Advanced Technology Park, Building No. 20, Haifa, Israel 31905
|
|
(Address of principal executive offices)
|
|
+972-74-710-7171
|
|
(Registrant’s telephone number)
|
|
Large accelerated filer
o
|
Accelerated filer
x
|
|
Non-accelerated filer
o
|
Smaller reporting company
o
|
|
(Do not check if a smaller reporting company)
|
|
Page
|
|
|
F - 2 - F - 3
|
|
|
F - 4
|
|
|
|
F - 5
|
|
F - 6 - F - 7
|
|
|
F - 8 - F - 9
|
|
|
F - 10 - F - 17
|
|
CONSOLIDATED
BALANCE
SHEETS
|
|
U.S. Dollars in thousands
|
|
September 30, 2012
|
June 30, 2012
|
||||||||||
|
Note
|
Unaudited
|
Audited
|
|||||||||
|
ASSETS
|
|||||||||||
|
CURRENT ASSETS:
|
|||||||||||
|
Cash and cash equivalents
|
$ | 38,751 | $ | 9,389 | |||||||
|
Short term bank deposits
|
21,434 | 21,397 | |||||||||
|
Marketable securities
|
3 | 8,129 | 7,023 | ||||||||
|
Other accounts receivable and prepaid expenses
|
1,668 | 383 | |||||||||
|
Total
current assets
|
69,982 | 38,192 | |||||||||
|
LONG-TERM ASSETS:
|
|||||||||||
|
Long-term deposits and restricted deposits
|
984 | 1,287 | |||||||||
|
Advance payment for leasehold improvements
|
3,428 | 2,400 | |||||||||
|
Property and equipment, net
|
6,440 | 5,019 | |||||||||
|
Severance pay fund
|
571 | 522 | |||||||||
|
Other long term assets
|
39 | - | |||||||||
|
Total
long-term assets
|
11,462 | 9,228 | |||||||||
|
Total
assets
|
$ | 81,444 | $ | 47,420 | |||||||
|
CONSOLIDATED BALANCE SHEETS
|
|
U.S. Dollars in thousands
|
|
September 30, 2012
|
June 30, 2012
|
||||||||||
|
Note
|
Unaudited
|
Audited
|
|||||||||
|
LIABILITIES AND STOCKHOLDERS’ EQUITY
|
|||||||||||
|
CURRENT LIABILITIES
|
|||||||||||
|
Trade payables
|
$ | 1,696 | $ | 1,368 | |||||||
|
Accrued expenses
|
1,069 | 922 | |||||||||
|
Deferred revenues
|
779 | 779 | |||||||||
|
Advance payment from United Therapeutics
|
959 | 1,576 | |||||||||
|
Other accounts payable
|
729 | 877 | |||||||||
|
Total
current liabilities
|
5,232 | 5,522 | |||||||||
|
LONG-TERM LIABILITIES
|
|||||||||||
|
Deferred revenues
|
3,310 | 3,505 | |||||||||
|
Accrued severance pay
|
709 | 651 | |||||||||
|
Total
long term liabilities
|
4,019 | 4,156 | |||||||||
|
COMMITMENTS AND CONTINGENCIES
|
5 | ||||||||||
|
STOCKHOLDERS’ EQUITY
|
|||||||||||
|
Share capital:
|
6 | ||||||||||
|
Common stock $0.00001 par value:
Authorized: 100,000,000 shares
Issued and outstanding: 57,257,230 shares as of
September 30, 2012, 46,448,051 shares as of June 30, 2012
|
- (*) | - (*) | |||||||||
|
Additional paid-in capital
|
141,836 | 103,619 | |||||||||
|
Accumulated deficit
|
(69,742 | ) | (65,747 | ) | |||||||
|
Other comprehensive gain (loss)
|
99 | (130 | ) | ||||||||
| 72,193 | 37,742 | ||||||||||
| $ | 81,444 | $ | 47,420 | ||||||||
|
(*)
|
Less than $1.
|
|
CONSOLIDATED STATEMENTS OF OPERATIONS
|
|
U.S. Dollars in thousands (except share and per share data)
|
|
Three months ended
September 30,
|
||||||||
|
2012
|
2011
|
|||||||
|
Unaudited
|
Unaudited
|
|||||||
|
Revenues
|
$ | 195 | $ | 154 | ||||
|
Cost of revenues
|
(6 | ) | (5 | ) | ||||
|
Gross profit
|
189 | 149 | ||||||
|
Research and development expenses
|
(3,748 | ) | (2,863 | ) | ||||
|
Less participation by the Office of the Chief Scientist and other parties
|
1,050 | 19 | ||||||
|
Research and development expenses, net
|
(2,698 | ) | (2,844 | ) | ||||
|
General and administrative expenses
|
(1,681 | ) | (1,637 | ) | ||||
|
Operating
loss
|
(4,190 | ) | (4,332 | ) | ||||
|
Financial income (expenses), net
|
195 | (161 | ) | |||||
|
Net loss for the period
|
$ | (3,995 | ) | $ | (4,493 | ) | ||
|
Loss per share:
|
||||||||
|
Basic and diluted net loss per share
|
$ | (0.08 | ) | $ | (0.11 | ) | ||
|
Weighted average number of shares used in computing basic and diluted net loss
per share
|
47,833,654 | 42,779,293 | ||||||
|
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)
|
|
U.S. Dollars in thousands
|
|
Three months ended
September 30,
|
||||||||
|
2012
|
2011 |
|
||||||
|
Unaudited
|
Unaudited
|
|||||||
|
Net loss
|
$ | (3,995 | ) | $ | (4,493 | ) | ||
|
Other comprehensive income, net of tax:
|
||||||||
|
Unrealized gain on available for sale marketable securities
|
229 | 1 | ||||||
|
Total comprehensive loss
|
$ | (3,766 | ) | $ | (4,492 | ) | ||
|
STATEMENTS OF CHANGES IN EQUITY (UNAUDITED)
|
|
U.S. Dollars in thousands (except share and per share data)
|
|
Common Stock
|
Additional Paid-in
|
Accumulated Other Comprehensive
|
Accumulated
|
Total
Stockholders’
|
||||||||||||||||||||
|
Shares
|
Amount
|
Capital
|
gain
|
Deficit
|
Equity
|
|||||||||||||||||||
|
Balance as of July 1, 2011
|
42,443,185 | $ | (*) | $ | 94,375 | $ | - | $ | (50,953 | ) | $ | 43,422 | ||||||||||||
|
Exercise of options by employees and consultants
|
12,500 | (*) | 8 | - | - | 8 | ||||||||||||||||||
|
Exercise of warrants by investors and finders
|
198,714 | (*) | 315 | - | - | 315 | ||||||||||||||||||
|
Stock based compensation to employees, directors
and non-employee consultants
|
330,844 | (*) | 1,041 | - | - | 1,041 | ||||||||||||||||||
|
Unrealized gain on available for sale marketable securities
|
- | - | - | 1 | - | 1 | ||||||||||||||||||
|
Net loss for the period
|
- | - | - | - | (4,493 | ) | (4,493 | ) | ||||||||||||||||
|
Balance as of September 30, 2011
|
42,985,243 | $ | (*) | $ | 95,739 | $ | 1 | $ | (55,446 | ) | $ | 40,294 | ||||||||||||
|
STATEMENTS OF CHANGES IN EQUITY (UNAUDITED)
|
|
U.S. Dollars in thousands (except share and per share data)
|
|
Common Stock
|
Additional Paid-in
|
Accumulated Other Comprehensive
|
Accumulated
|
Total
Stockholders’
|
||||||||||||||||||||
|
Shares
|
Amount
|
Capital
|
Income (Loss)
|
Deficit
|
Equity
|
|||||||||||||||||||
|
Balance as of July 1, 2012
|
46,448,051 | $ | (*) | $ | 103,619 | $ | (130 | ) | $ | (65,747 | ) | $ | 37,742 | |||||||||||
|
Issuance of common stock and warrants related to
September 2012 public offering, net of issuance
costs of $2,694
|
9,200,000 | (*) | 34,106 | - | - | 34,106 | ||||||||||||||||||
|
Exercise of options by employees and consultants
|
94,332 | (*) | 146 | - | - | 146 | ||||||||||||||||||
|
Exercise of warrants by investors and finders
|
975,622 | (*) | 1,229 | - | - | 1,229 | ||||||||||||||||||
|
Stock based compensation to employees, directors and non-employee consultants
|
539,225 | (*) | 1,336 | - | - | 1,336 | ||||||||||||||||||
|
Stock based compensation to contractor
|
- | - | 1,400 | - | - | 1,400 | ||||||||||||||||||
|
Unrealized gain on available for sale marketable securities
|
- | - | - | 229 | - | 229 | ||||||||||||||||||
|
Net loss for the period
|
- | - | - | - | (3,995 | ) | (3,995 | ) | ||||||||||||||||
|
Balance as of September 30, 2012
|
57,257,230 | $ | (*) | $ | 141,836 | $ | 99 | $ | (69,742 | ) | $ | 72,193 | ||||||||||||
|
CONSOLIDATED STATEMENTS OF CASH FLOWS
|
|
U.S. Dollars in thousands
|
|
Three months ended September 30,
|
||||||||
|
2012
|
2011
|
|||||||
|
Unaudited
|
Unaudited
|
|||||||
|
CASH FLOWS FROM OPERATING ACTIVITIES:
|
||||||||
|
Net loss
|
$ | (3,995 | ) | $ | (4,493 | ) | ||
|
Adjustments to reconcile net loss to net cash used in operating activities:
|
||||||||
|
Depreciation
|
130 | 97 | ||||||
|
Capital loss
|
- | - | ||||||
|
Stock-based compensation to employees, directors and non-employee consultants
|
1,063 | 1,041 | ||||||
|
Stock compensation to investor relations consultants
|
273 | 1 | ||||||
|
Increase in other accounts receivable
|
(746 | ) | (76 | ) | ||||
|
Increase in prepaid expenses
|
(483 | ) | (20 | ) | ||||
|
Decrease (increase) in trade payables
|
988 | (87 | ) | |||||
|
Increase in other accounts payable and accrued expenses
|
30 | 205 | ||||||
|
Increase (decrease) in deferred revenues
|
(195 | ) | 4,846 | |||||
|
Increase (decrease) in advance payment from United Therapeutics
|
(617 | ) | 2,000 | |||||
|
Linkage differences and Increase (decrease) interest on short and long-term deposit and restricted lease deposit
|
(37 | ) | 55 | |||||
|
Accretion of discount, amortization of premium and changes in accrued interest from marketable securities
|
43 | 4 | ||||||
|
Loss (gain) from sale of investments of available for sale marketable securities
|
15 | - | ||||||
|
Accrued severance pay, net
|
9 | (1 | ) | |||||
|
Net cash used in (provided by) operating activities
|
$ | (3,522 | ) | $ | 3,461 | |||
|
CASH FLOWS FROM INVESTING ACTIVITIES:
|
||||||||
|
Purchase of property and equipment
|
$ | (1,978 | ) | $ | (179 | ) | ||
|
Investment in short-term deposits
|
- | (31,599 | ) | |||||
|
Repayment (Investment) in long-term deposits
|
300 | (690 | ) | |||||
|
Repayment of long-term restricted deposit
|
3 | 4 | ||||||
|
Proceeds from sale and redemption of available for sale marketable securities
|
313 | - | ||||||
|
Investment in available for sale marketable securities
|
(1,248 | ) | (516 | ) | ||||
|
Net cash used in investing activities
|
$ | (2,610 | ) | $ | (32,980 | ) | ||
|
CONSOLIDATED STATEMENTS OF CASH FLOWS
|
|
U.S. Dollars in thousands
|
|
Three months ended September 30,
|
||||||||
|
2012
|
2011
|
|||||||
|
Unaudited
|
Unaudited
|
|||||||
|
CASH FLOWS FROM FINANCING ACTIVITIES:
|
||||||||
|
Issuance of common stock and warrants, net of issuance costs
|
$ | 34,106 | $ | - | ||||
|
Exercise of warrants and options
|
1,388 | 323 | ||||||
|
Net cash provided by financing activities
|
$ | 35,494 | $ | 323 | ||||
|
Increase (decrease) in cash and cash equivalents
|
29,362 | (29,196 | ) | |||||
|
Cash and cash equivalents at the beginning of the period
|
9,389 | 42,829 | ||||||
|
Cash and cash equivalents at the end of the period
|
$ | 38,751 | $ | 13,633 | ||||
|
(a) Supplemental disclosure of cash flow activities:
|
||||||||
|
Cash paid during the period for:
|
||||||||
|
Taxes paid due to non-deductible expenses
|
$ | 3 | $ | 8 | ||||
|
(b) Supplemental disclosure of non-cash activities:
|
||||||||
|
Purchase of property and equipment on credit
|
$ | 78 | $ | 109 | ||||
|
Stock based compensation to contractor
|
$ | 1,400 | $ | - | ||||
|
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
|
|
U.S. Dollars in thousands (except per share amounts)
|
|
|
a.
|
Pluristem Therapeutics Inc., a Nevada corporation, was incorporated on May 11, 2001. Pluristem Therapeutics Inc. has a wholly owned subsidiary, Pluristem Ltd. (the “Subsidiary”), which is incorporated under the laws of the State of Israel. Pluristem Therapeutics Inc. and the Subsidiary are referred to as the “Company”.
|
|
|
b.
|
The Company is a bio-therapeutics company developing standardized cell therapy products from human placenta for the treatment of multiple disorders. The Company has sustained operating losses and expects such losses to continue in the foreseeable future. The Company's accumulated losses aggregated to $69,742 through September 30, 2012 and the Company incurred a net loss of $3,995 for the three months ended September 30, 2012. There is no assurance that profitable operations, if ever achieved, could be sustained on a continuing basis.
The Company plans to continue to finance its operations with sales of equity securities, entering into licensing technology agreements such as the United Therapeutics Corporation (“United Therapeutics”) agreement, and from grants to support its R&D activity. In the longer term, the Company plans to finance its operations from revenues from sales of products.
|
|
|
a.
|
Unaudited Interim Financial Information
|
|
|
Operating results for the three months ended September 30, 2012 are not necessarily indicative of the results that may be expected for the year ending June 30, 2013. For further information, reference is made to the consolidated financial statements and footnotes thereto included in the Company’s Annual Report on Form 10-K for the year ended June 30, 2012.
|
|
|
b.
|
Fair value of financial instruments:
|
|
|
The carrying amounts of the Company's financial instruments, including cash and cash equivalents, available-for-sale marketable securities, short-term deposits, trade payable and other accounts payable and accrued liabilities, approximate fair value because of their generally short term maturities.
|
|
|
The Company accounts for certain assets and liabilities at fair value under ASC 820, “Fair Value Measurements and Disclosures.” Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or a liability. As a basis for considering such assumptions, ASC 820 establishes a three-tier value hierarchy, which prioritizes the inputs used in the valuation methodologies in measuring fair value:
|
|
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
|
|
U.S. Dollars in thousands (except per share amounts)
|
|
b.
|
Fair value of financial instruments (cont.)
|
|
|
Level 1 -
Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets;
|
|
|
Level 2 -
Includes other inputs that are directly or indirectly observable in the marketplace, other than quoted prices included in Level 1, such as quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets with insufficient volume or infrequent transactions, or other inputs that are observable (model-derived valuations in which significant inputs are observable), or can be derived principally from or corroborated by observable market data; and
|
|
|
Level 3 -
Unobservable inputs which are supported by little or no market activity.
|
|
c.
|
Derivative financial instruments
|
|
|
d.
|
Impact of recently issued accounting standards:
|
|
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
|
|
U.S. Dollars in thousands (except per share amounts)
|
|
September 30, 2012
|
June 30,2012
|
|||||||||||||||||||||||||||||||
|
Amortized cost
|
Gross
unrealized
gain
|
Gross
unrealized
loss
|
Fair
value
|
Amortized cost
|
Gross
unrealized
gain
|
Gross
unrealized
loss
|
Fair
value
|
|||||||||||||||||||||||||
|
Available-for-sale - matures within one year:
|
||||||||||||||||||||||||||||||||
|
Stock and index linked notes
|
$ | 1,294 | $ | 105 | $ | (36 | ) | $ | 1,363 | $ | 1,264 | $ | 57 | $ | (56 | ) | $ | 1,265 | ||||||||||||||
|
Government debentures – fixed interest rate
|
152 | 4 | - | 156 | 57 | - | - | 57 | ||||||||||||||||||||||||
|
Corporate debentures – fixed interest rate
|
304 | 6 | (1 | ) | 309 | 303 | 2 | (2 | ) | 303 | ||||||||||||||||||||||
| $ | 1,750 | $ | 115 | $ | (37 | ) | $ | 1,828 | $ | 1,624 | $ | 59 | $ | (58 | ) | $ | 1,625 | |||||||||||||||
|
Available-for-sale - matures after one year through five years:
|
||||||||||||||||||||||||||||||||
|
Government debentures – fixed interest rate
|
1,366 | 18 | (37 | ) | 1,347 | 1,417 | 12 | (42 | ) | 1,387 | ||||||||||||||||||||||
|
Corporate debentures – fixed interest rate
|
4,042 | 89 | (33 | ) | 4,098 | 2,829 | 20 | (57 | ) | 2,792 | ||||||||||||||||||||||
| $ | 5,408 | $ | 107 | $ | (70 | ) | $ | 5,445 | $ | 4,246 | $ | 32 | $ | (99 | ) | $ | 4,179 | |||||||||||||||
|
Available-for-sale - matures after five years through ten years:
|
||||||||||||||||||||||||||||||||
|
Government debentures – fixed interest rate
|
427 | 2 | (12 | ) | 417 | 467 | - | (23 | ) | 444 | ||||||||||||||||||||||
|
Corporate debentures – fixed interest rate
|
445 | 2 | (8 | ) | 439 | 816 | 3 | (44 | ) | 775 | ||||||||||||||||||||||
| $ | 872 | $ | 4 | $ | (20 | ) | $ | 856 | $ | 1,283 | $ | 3 | $ | (67 | ) | $ | 1,219 | |||||||||||||||
| $ | 8,030 | $ | 226 | $ | (127 | ) | $ | 8,129 | $ | 7,153 | $ | 94 | $ | (224 | ) | $ | 7,023 | |||||||||||||||
|
September 30, 2012
|
June 30, 2012
|
|||||||||||||||||||||||
|
Level 1
|
Level 2
|
Level 3
|
Level 1
|
Level 2
|
Level 3
|
|||||||||||||||||||
|
Marketable securities
|
$ | 4,234 | $ | 3,895 | - | $ | 4,181 | $ | 2,842 | $ | - | |||||||||||||
|
Derivatives
|
- | 15 | - | - | (138 | ) | - | |||||||||||||||||
|
Total
|
$ | 4,234 | $ | 3,910 | $ | - | $ | 4,181 | $ | 2,704 | $ | - | ||||||||||||
|
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
|
|
U.S. Dollars in thousands (except per share amounts)
|
|
|
Commitments and contingencies that changed during the three months ended September 30, 2012 include the following:
|
|
|
a.
|
Decrease in the amount of $300 of cash pledged by the Company to secure its hedging transactions, credit line and bank guarantees.
|
|
|
a.
|
As part of the agreement for building the new Company's facility with Biopharmax Group Ltd ("Biopharmax"), the Company issued 1,500,000 shares of common stock to Biopharmax during fiscal year 2012. Total consideration from selling the shares amounted to $5,071. As of September 30, 2012 a balance of $3,428 was recorded in the Company balance sheet as an advanced payment asset from the total consideration.
|
|
|
b.
|
In July through September 2012, a total of 479,532 warrants were exercised via a “cashless” manner, resulting in the issuance of 287,483 shares of common stock to investors of the Company. The Company has a commitment to issue additional 28,860 shares of common stock to one of its shareholders. In addition, 688,139 warrants were exercised and resulted in the issuance of 688,139 shares of common stock to investors of the Company. The aggregate cash consideration received was $1,229.
|
|
|
c.
|
On September 19, 2012, the Company closed a firm commitment underwritten public offering of 8,000,000 units, at a purchase price of $4.00 per unit, with each unit consisting of one share of the Company's common stock and one warrant to purchase 0.35 shares of common stock, at a purchase price of $5.00 per share. The warrants sold in the offering will be exercisable on March 19, 2013 and expire on September 19, 2017. The Company has also granted the underwriters a 30-day option to purchase up to 1,200,000 shares of common stock and/or warrants to purchase up to 420,000 shares of common stock. As of September 24, 2012 the underwriters fully exercised their option. The aggregate net proceeds to the Company from the offering, including from the exercise in full of the option, are $34,106, before the exercise of any warrants (which has not yet occurred) and after deducting underwriting commissions and discounts and offering expenses of the Company.
|
|
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
|
|
U.S. Dollars in thousands (except per share amounts)
|
|
|
d.
|
Options, warrants, restricted stock and restricted stock units to employees, directors and consultants:
|
|
|
1.
|
Options to employees and directors:
|
|
Three months ended September 30, 2012
|
||||||||||||||||
|
Number
|
Weighted Average Exercise Price
|
Weighted Average Remaining Contractual Terms (in years)
|
Aggregate Intrinsic Value Price
|
|||||||||||||
|
Options outstanding at beginning of period
|
2,082,172 | $ | 3.87 | |||||||||||||
|
Options exercised
|
(74,332 | ) | 1.57 | |||||||||||||
|
Options outstanding at end of the period
|
2,007,840 | $ | 3.95 | 4.72 | $ | 1,968 | ||||||||||
|
Options exercisable at the end of the period
|
2,007,840 | $ | 3.95 | 4.72 | $ | 1,968 | ||||||||||
|
Options vested
|
2,007,840 | $ | 3.95 | 4.72 | $ | 1,968 | ||||||||||
|
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
|
|
U.S. Dollars in thousands (except per share amounts)
|
|
d.
|
Options, warrants, restricted stock and restricted stock units to employees,
directors and consultants (cont.):
|
|
|
2.
|
Options and warrants to non-employees:
|
|
Three months ended September 30, 2012
|
||||||||||||||||
|
Number
|
Weighted Average Exercise Price
|
Weighted Average Remaining Contractual Terms (in years)
|
Aggregate Intrinsic Value Price
|
|||||||||||||
|
Options and warrants outstanding at beginning of period
|
382,000 | $ | 3.86 | |||||||||||||
|
Options and warrants exercised
|
(56,000 | ) | 1.34 | |||||||||||||
|
Options and warrants outstanding at end of the period
|
326,000 | $ | 4.29 | 4.90 | $ | 657 | ||||||||||
|
Options and warrants exercisable at the end of the period
|
314,000 | $ | 4.46 | 4.75 | $ | 609 | ||||||||||
|
Options and warrants vested
|
326,000 | $ | 4.29 | 4.90 | $ | 657 | ||||||||||
|
|
Compensation expenses related to options and warrants granted to consultants were recorded as follows:
|
|
Three months ended
September 30,
|
||||||||
|
2012
|
2011
|
|||||||
|
Research and development expenses
|
$ | - | $ | 10 | ||||
|
General and administrative expenses
|
18 | 7 | ||||||
| $ | 18 | $ | 17 | |||||
|
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
|
|
U.S. Dollars in thousands (except per share amounts)
|
|
d.
|
Options, warrants, restricted stock and restricted stock units to employees,
directors and consultants (cont.):
|
|
|
3.
|
Restricted stock and restricted stock units to employees and directors:
|
|
Number
|
||||
|
Unvested at the beginning of period
|
2,085,276 | |||
|
Granted
|
13,000 | |||
|
Forfeited
|
(37,213 | ) | ||
|
Vested
|
(462,497 | ) | ||
|
Unvested at the end of the period
|
1,598,566 | |||
|
Expected to vest after September 30, 2012
|
1,566,803 | |||
|
Three months ended
September 30,
|
||||||||
|
2012
|
2011
|
|||||||
|
Research and development expenses
|
$ | 317 | $ | 253 | ||||
|
General and administrative expenses
|
608 | 679 | ||||||
| $ | 925 | $ | 932 | |||||
|
|
Future expenses related to restricted stock and restricted stock units granted to employees and directors for an average time of approximately two years is $1,512.
|
|
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
|
|
U.S. Dollars in thousands (except per share amounts)
|
|
d.
|
Options, warrants, restricted stock and restricted stock units to employees,
directors and consultants (cont.):
|
|
|
4.
|
Restricted stock and restricted stock units to consultants:
|
|
Number
|
||||
|
Unvested at the beginning of period
|
66,000 | |||
|
Granted
|
66,228 | |||
|
Vested
|
(76,728 | ) | ||
|
Unvested at the end of the period
|
55,500 | |||
|
Expected to vest after September 30, 2012
|
55,500 | |||
|
Three months ended
September 30,
|
||||||||
|
2012
|
2011
|
|||||||
|
Research and development expenses
|
$ | 120 | $ | 92 | ||||
|
General and administrative expenses
|
273 | - | ||||||
| $ | 393 | $ | 92 | |||||
|
4.1*
|
Warrant Agreement dated September 19, 2012, by and between the registrant and American Stock Transfer & Trust Company, LLC (including the form of Warrant certificate).
|
|
31.1*
|
Rule 13a-14(a) Certification of Chief Executive Officer.
|
|
31.2*
|
Rule 13a-14(a) Certification of Chief Financial Officer.
|
|
32.1**
|
Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350.
|
|
32.2**
|
Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350.
|
|
101 **
|
The following materials from our Quarterly Report on Form 10-Q for the quarter ended September 30, 2012 formatted in XBRL (eXtensible Business Reporting Language): (i) the Consolidated Balance Sheets, (ii) the Consolidated Statements of Operations, (iii) the Consolidated Statements of Comprehensive Income (Loss), (iv) the Statements of Changes in Equity, (v) the Consolidated Statements of Cash Flows, and (vi) the Notes to Consolidated Financial Statements, tagged as blocks of text and in detail.
|
No information found
* THE VALUE IS THE MARKET VALUE AS OF THE LAST DAY OF THE QUARTER FOR WHICH THE 13F WAS FILED.
| FUND | NUMBER OF SHARES | VALUE ($) | PUT OR CALL |
|---|
| DIRECTORS | AGE | BIO | OTHER DIRECTOR MEMBERSHIPS |
|---|
No information found
No Customers Found
No Suppliers Found
Price
Yield
| Owner | Position | Direct Shares | Indirect Shares |
|---|